Drug intelligence / Profile preview

PRS MioBoost

Development stage: Preclinical
Lead developer: Peaches Biotech
Modality: Cell Therapies

Overview

PRS MioBoost is an allogeneic biological therapy developed by Peaches Biotech for the treatment of muscle degeneration and sports-related injuries. Utilizing the proprietary PRS (Selective Rich Plasma) platform, the drug is produced through a patented co-culture method that generates a specific secretome containing selective growth factors and immunomodulatory signals. These signals are derived from stem cells and are designed to promote muscle regeneration and modulate the immune response within damaged muscle tissue. Currently in preclinical development, PRS MioBoost is part of a broader pipeline of biological products aimed at tissue regeneration.

Other names: PRS Mio Boost

Beyond the preview

Go deeper on PRS MioBoost.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRS MioBoost.

Explore the full profile